Vestmark Advisory Solutions Inc. Raises Stock Holdings in Insulet Corporation $PODD

Key Points

• Vestmark Advisory Solutions Inc. increased its stake in Insulet Corporation (NASDAQ:PODD) by 99.1% in the first quarter, bringing its total holdings to 2,118 shares valued at $556,000.
• Insulet's stock rose 1.7% to $333.00 with a market capitalization of $23.44 billion, and it reported a quarterly earnings per share (EPS) of $1.17, exceeding analyst estimates.
• Wall Street analysts have issued mostly buy ratings for Insulet, with a consensus price target around $330.71.

Vestmark Advisory Solutions Inc. boosted its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 99.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,118 shares of the medical instruments supplier's stock after purchasing an additional 1,054 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Insulet were worth $556,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PODD. OLD National Bancorp IN boosted its holdings in shares of Insulet by 6.7% in the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after buying an additional 55 shares during the last quarter. Cooper Financial Group raised its position in Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock worth $283,000 after acquiring an additional 58 shares during the period. Syon Capital LLC raised its position in Insulet by 5.6% in the fourth quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock worth $291,000 after acquiring an additional 59 shares during the period. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Insulet by 23.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after acquiring an additional 59 shares during the last quarter. Finally, HighTower Advisors LLC grew its position in shares of Insulet by 2.1% during the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock valued at $757,000 after acquiring an additional 60 shares during the period.

Insulet Price Performance

Shares of Insulet stock traded up $2.92 on Friday, hitting $330.77. 499,504 shares of the company traded hands, compared to its average volume of 705,185. Insulet Corporation has a 52 week low of $180.31 and a 52 week high of $334.18. The business has a 50-day simple moving average of $300.94 and a 200 day simple moving average of $285.91. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a market capitalization of $23.28 billion, a P/E ratio of 100.54, a price-to-earnings-growth ratio of 2.77 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's quarterly revenue was up 32.9% on a year-over-year basis. During the same period last year, the company posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Canaccord Genuity Group raised their target price on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Citigroup restated a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Finally, Wells Fargo & Company increased their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.